[Today's IR] GAON Group and Biotoxtech
Predicted impact: Low
Routine investor relations event, already reported in the past 14 days.
Biotoxtech바이오톡스텍
086040 · KOSDAQ · ₩086040 · 바이오톡스텍
₩2,080▲ ₩35 (1.71%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −26.24%
- Market cap
- ₩33B
- Enterprise value
- ₩60B
- P/E
- —
- P/B
- 1.0×
- Dividend yield
- 0.0%
- ROE
- −12.3%
- Net margin
- −7.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−49.5% from the high
₩1,896Today: ₩2,045 – ₩2,090₩4,115
Returns
- 1W+2.5%
- 1M−7.1%
- 3M−2.6%
- 6M−38.2%
- YTD−26.1%
- 1Y−26.2%
- Volume today
- 1,718
- 0.2× the 20-day average
- Traded today
- ₩3.6M
- Listed shares
- 15,958,247
- EPS (12 months)
- −₩250
- Earnings yield −12.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Routine ownership filings with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-9.2% over the last month; the price is below its 20-day average.
- News impactLow4 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Biotoxtech stock overview
Biotoxtech (바이오톡스텍, KRX: 086040) is listed on KOSDAQ, in the Biotech & Pharma sector. Bio-Toxtech operates a non-clinical contract research organization (CRO) business that conducts safety and toxicity evaluations of medicines, cell and gene therapies, and chemical substances for clients, with its main subsidiary Keyprime Research performing primate-based safety and efficacy testing. Its shares closed at ₩2,080 on Oct 27, 2026, up 1.71% on the day, giving it a market value of ₩33B.
Key facts
- Market cap
- ₩33B
- Sector
- Biotech & Pharma
- Latest price change
- +1.71%
- As of
- Oct 27, 2026
- Main business
- Bio-Toxtech operates a non-clinical contract research organization (CRO) business that conducts safety and toxicity evaluations of medicines, cell and gene therapies, and chemical substances for clients, with its main subsidiary Keyprime Research performing primate-based safety and efficacy testing.
Quick answers about Biotoxtech
- What does Biotoxtech do?
- Bio-Toxtech operates a non-clinical contract research organization (CRO) business that conducts safety and toxicity evaluations of medicines, cell and gene therapies, and chemical substances for clients, with its main subsidiary Keyprime Research performing primate-based safety and efficacy testing. Its revenue comes almost entirely from non-clinical testing services, sold through direct marketing to domestic and overseas clients under contracts for each study. The company also develops drug candidates such as TB-4 and HX-1171, has licensed TB-4 eye-related rights to Huons, and is pursuing further licensing of its pipeline.
- What is the market cap of Biotoxtech?
- The market capitalisation of Biotoxtech was ₩33B at the close on Oct 27, 2026.
- Who are the largest shareholders of Biotoxtech?
- According to the latest official filings, the largest reported holders are Kang Jong-gu (24.31%, as of Oct 26, 2026); S&P Asset Management (3.59%, as of Nov 25, 2024); Jeong Su-yong (0.66%, as of Aug 6, 2026).
- When is the next earnings report from Biotoxtech?
- Korean companies rarely announce results dates in advance. Based on when Biotoxtech filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
Bio-Toxtech operates a non-clinical contract research organization (CRO) business that conducts safety and toxicity evaluations of medicines, cell and gene therapies, and chemical substances for clients, with its main subsidiary Keyprime Research performing primate-based safety and efficacy testing. Its revenue comes almost entirely from non-clinical testing services, sold through direct marketing to domestic and overseas clients under contracts for each study. The company also develops drug candidates such as TB-4 and HX-1171, has licensed TB-4 eye-related rights to Huons, and is pursuing further licensing of its pipeline.
Written by AI from the company's latest annual report.
- Korean name
- 바이오톡스텍
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 강종구
- Founded
- Aug 2000
- Listed
- Sep 2007
- Listed shares
- 15,958,247
- Fiscal year ends
- Month 12
- Website
- www.biotoxtech.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Insider shareholding reportOct 26, 2026
- 5%+ holding reportOct 26, 2026
- Investor relations (IR) eventOct 20, 2026
- Acquisition of Bonds Before Maturity After Issuance of Bonds with Warrants (Including Overseas Bonds with Warrants)Oct 8, 2026
- Insider shareholding reportSep 23, 2026
Titles in Korean until English translations are added.
Also known as: Biotoxtech / 바이오톡스텍 / 086040 / KRX:086040
Source: KRX statistical information